<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393586</url>
  </required_header>
  <id_info>
    <org_study_id>Faro-WBA</org_study_id>
    <nct_id>NCT02393586</nct_id>
  </id_info>
  <brief_title>Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</brief_title>
  <official_title>Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single Doses of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bactericidal activity against Mycobacterium
      tuberculosis of faropenem boosted with amoxicillin/clavulanic acid. Pharmacokinetics (PK) and
      Whole blood Bactericidal Activity (WBA) will be measured in healthy volunteers following
      single doses of faropenem plus amoxicillin/clavulanic acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      WBA is an ex vivo model for measuring the combined effects of administered drugs, host
      factors and strain factors on mycobacterial killing. If performed in parallel with PK
      measurements, the method can be used to evaluate the effect of drugs throughout the dosing
      cycle. The aim of this trial is to investigate the bactericidal activity of faropenem
      administered with amoxicillin/clavulanic acid (augmentin) using the WBA model. We will also
      explore whether there is any additive effect or synergy with rifampicin in this model. The
      activity of faropenem on WBA by different strains of M. tuberculosis will be compared and the
      relationship between the host immune profile and WBA will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative WBA</measure>
    <time_frame>8 hours</time_frame>
    <description>Cumulative bactericidal activity (WBA) reported as change in Mtb log CFU per day based on values observed (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic profile of study drug(s)</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Faropenem/augmentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampicin/faropenem/augmentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifampicin 10mg/kg plus faropenem 600mg plus amoxicillin/clavulanic acid 500mg/125mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifampicin 10mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faropenem</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Faropenem/augmentin</arm_group_label>
    <arm_group_label>Rifampicin/faropenem/augmentin</arm_group_label>
    <other_name>Faropenem sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin/clavulanic acid 500mg/125mg</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Faropenem/augmentin</arm_group_label>
    <arm_group_label>Rifampicin/faropenem/augmentin</arm_group_label>
    <other_name>Augmentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Single oral dose</description>
    <arm_group_label>Rifampicin/faropenem/augmentin</arm_group_label>
    <arm_group_label>Rifampicin</arm_group_label>
    <other_name>Rifampin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 21 and above

          2. Male or female willing to comply with the study visits and procedures

          3. Willing and able to provide written informed consent

        Exclusion Criteria:

          1. Women who are currently pregnant or breastfeeding

          2. Signs of active TB

          3. Previous hypersensitivity or allergy to rifampicin, faropenem or other beta-lactam
             drugs (penicillins, carbapenems)

          4. Current use of any drugs or medications known to have an interaction with any of the
             study drugs

          5. Current use of any other drugs, over the counter or herbal preparations that are known
             or potential inhibitors or inducers of cytochrome P450 enzymes

          6. Evidence of renal or hepatic dysfunction or any clinically significant deviation from
             normal during screening including laboratory determinations

          7. Known hepatic disease or alcohol abuse

          8. Any other significant condition that would, in the opinion of the investigator,
             compromise the volunteer's safety or outcome in the trial

          9. Current participation in other clinical intervention trial or research protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Paton</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Whole blood Bactericidal Activity</keyword>
  <keyword>WBA</keyword>
  <keyword>Faropenem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>Link to Pubmed (Final publication)</doc_type>
      <doc_url>https://www.ncbi.nlm.nih.gov/pubmed/28333342</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

